C
Context Therapeutics Inc.
Period
FY 2025
Revenue
—
Net Income
$-36.12M
Total Assets
$68.49M
Equity
$60.47M
Shares Out
91.88M
Op. Cash Flow
$-26.39M
Business
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. The company is advancing three product candidates: CTIM-76 (CLDN6 x CD3 TCE), CT-95 (MSLN x CD3 TCE), and CT-202 (Nectin-4 x CD3 TCE), with CTIM-76 and CT-95 in Phase 1 trials and CT-202 preparing for first-in-human dosing. Development and commercialization activities are planned for global markets, with potential partnerships for expansion and commercialization.
Summary from 10-K filed 2026-03-23
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 32 | 23 | 18 | 7 | 4 | |
| General and administrative | 8 | 7 | 7 | 8 | 4 | |
| Loss from operations | −40 | −30 | −25 | −15 | −11 | |
| Interest income | 3 | 3 | 1 | — | — | |
| Other income (expense) | 200,471 | −1,428 | −55,570 | — | — | |
| Net loss | −36 | −27 | −24 | −15 | −10 | |
| Net income (loss) per share - basic (in dollars per share) | −0.38 | −0.46 | −1.5 | −0.93 | −3.69 | |
| Net income (loss) per share - diluted (in dollars per share) | −0.38 | −0.46 | −1.5 | −0.93 | −3.69 | |
| Weighted average common shares outstanding - basic (in shares) | 95 | 58 | 16 | 16 | 3 | |
| Weighted average common shares outstanding - diluted (in shares) | 95 | 58 | 16 | 16 | 3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 66 | 94 | 14 | 35 | 50 | |
| Prepaid expenses and other current assets | 2 | 3 | 2 | 2 | 2 | |
| Total current assets | 68 | 98 | 16 | 38 | 51 | |
| Operating lease right-of-use asset | 100,000 | 218,816 | 0 | 51,967 | 0 | |
| Property and equipment, net | 29,656 | 11,959 | 15,524 | 27,568 | 0 | |
| Total assets | 68 | 98 | 16 | 38 | 51 | |
| Accounts payable | 3 | 1 | 2 | 936,330 | 2 | |
| Accrued expenses and other current liabilities | 5 | 1 | 2 | 2 | 1 | |
| Operating lease liability - current | 112,064 | 107,316 | 0 | 55,078 | 0 | |
| Total current liabilities | 8 | 3 | 4 | 3 | 3 | |
| Operating lease liabilities - non-current | 0 | 112,064 | 0 | — | — | |
| Total liabilities | 8 | 3 | 4 | 3 | 3 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock$0.001 par value; 200,000,000 shares authorized; 91,879,177 and 89,704,194 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 91,879 | 89,704 | 15,966 | 15,966 | 15,966 | |
| Additional paid-in capital | 191 | 190 | 80 | 79 | 78 | |
| Accumulated deficit | −131 | −95 | −68 | −44 | −29 | |
| Total stockholders' equity | 60 | 95 | 12 | 35 | 48 | |
| Total liabilities and stockholders' equity | 68 | 98 | 16 | 38 | 51 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research And Development Expense, Acquired In Process | 2 | 15 | 0 | — | — | |
| Share-based compensation expense | 1 | 841,867 | 1 | 976,440 | 511,079 | |
| Depreciation and amortization expense | 16,251 | 10,881 | 12,044 | 9,268 | 0 | |
| Reduction in the carrying amount of operating lease right-of-use asset | 108,406 | 41,822 | 51,967 | 78,521 | 0 | |
| Prepaid expenses and other current assets | 1 | −2 | 758,829 | −736,049 | −2 | |
| Accounts payable | 1 | −946,096 | 1 | −787,893 | −866,007 | |
| Accrued expenses and other current liabilities | 4 | −619,770 | −407,470 | 1 | 252,655 | |
| Operating lease liability | −107,316 | −41,258 | −55,078 | −75,410 | 0 | |
| Cash used in operating activities | −26 | −15 | −21 | −14 | −9 | |
| Acquired in-process research and development | −2 | −15 | 0 | −500,000 | −250,000 | |
| Purchase of property and equipment | −33,948 | −7,316 | 0 | −36,836 | 0 | |
| Cash used in investing activities | −2 | −15 | 0 | −536,836 | −250,000 | |
| Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs | 0 | 95 | 0 | 0 | 29 | |
| Payment of offering costs from the sale of common stock from ATM facility | −15,268 | 0 | 0 | −102,071 | −100,000 | |
| Proceeds from the sale of common stock from ATM facility, net | 0 | 15 | 0 | — | — | |
| Cash (used in) provided by financing activities | −15,268 | 109 | 0 | −102,071 | 58 | |
| Net (decrease) increase in cash and cash equivalents | −28 | 80 | −21 | −14 | 49 | |
| Cashless exercise of prefunded warrants from private placement | 2,175 | 0 | 0 | 345,530 | 0 | |
| Unpaid offering costs in Accounts payable | 0 | 15,268 | — | — | — | |
| Right-of-use asset acquired under operating lease | 0 | 260,638 | 0 | 130,488 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Context Therapeutics Inc.'s CIK number?
Context Therapeutics Inc.'s SEC CIK number is 0001842952 (1842952). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Context Therapeutics Inc.'s SEC filings?
All of Context Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.